The Human Microbiome Market growth for 2020 is estimated at 14.20% and the incremental growth of the market is anticipated to be $ 286.89 million over 2024.
The microbiome is the genetic material of all the microbes - bacteria, fungi, protozoa and viruses - that live on and inside the human body. The number of genes in all the microbes in one person's microbiome is 200 times the number of genes in the human genome. There are a number of organizations that are developing products across various disease areas in the human microbiome space. Companies have developed their own proprietary technology platforms and innovative approaches to microbiome-based treatment.
Microbiome market key players are Enterome Bioscience, Yakult, DuPont, Seres Therapeutics, Vithera Pharmaceuticals, Second Genome Inc., Synthetic Biologics Inc., Vedanta Biosciences Inc., and Osel Inc.
Enterome research for next generation is pioneering the discovery and development of pharmaceuticals based on its unrivalled understandings of the interaction between the gut microbiome and the immune system. By using these focus on diseases like cancer, autoimmune, inflammatory and metabolic diseases. According to scientific research, the microbes in your gut could predict whether you’re likely to die in the next 15 years. The mix of microbes in our gut can reveal the presence of many diseases better than our own genes can even anticipate our risk of dying within the next 15 years.
After years of monitoring the body’s microbial communities, researchers are now starting to modify them to treat disease. Put the gut microbes from an obese mouse into the body of a lean one, and the latter will pack on weight even without changes to its diet, activity, or other habits. Such studies have made it increasingly clear that an organism’s commensal microbes can have powerful health effects, including in humans. A decade of research suggests that our microbiota help drive brain development, spur immune-system development or allergies and might trigger certain cancers. These observations have spawned industries that offer probiotics, prebiotics, personal microbiota sequencing, and more.
The MIcrobiome market segmentation is based on Type, Application and Region. By type it has (Probiotics, Prebiotics, Symbiotic). By Application (Gastrointestinal Disorders, Immunological Conditions and Others).By region it has been (North America, Europe, Asia-Pacific and Rest of the world). North America currently dominates the market for human microbiome due to the rising incidences of life style related diseases and autoimmune disorders in these regions. However, Asia Pacific is also expected to show a high growth rate due to improving research infrastructure in the region.